Yiying Zhou

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

Josef S Smolen, Jonathan Kay, Mittie K. Doyle et al. · The Lancet · 2009 · 516 citations

Rheumatoid Disorder, Rheumatology, Autoimmune Disease +11

Three Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis

Atul Deodhar, Lianne S. Gensler, Joachim Sieper et al. · Arthritis & Rheumatology · 2018 · 311 citations · Full text

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study

Atul Deodhar, Jürgen Braun, Robert D. Inman et al. · Annals of the Rheumatic Diseases · 2014 · 141 citations · Full text

Fucoxanthin Inhibits β-Amyloid Assembly and Attenuates β-Amyloid Oligomer-Induced Cognitive Impairments

Siying Xiang, Fufeng Liu, Jiajia Lin et al. · Journal of Agricultural and Food Chemistry · 2017 · 136 citations

Aβ Assembly, Neurochemical Biomarkers, Peptide Science +18

Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study)

Arthur Kavanaugh, Iain B. McInnes, Philip J. Mease et al. · Annals of the Rheumatic Diseases · 2014 · 125 citations · Full text